-
公开(公告)号：US20080248043A1
公开(公告)日：2008-10-09
申请号：US11805129
申请日：2007-05-21
IPC分类号： A61K39/395 , C07K16/18 , C12N5/06 , C12N15/11 , C12N15/00 , A01K67/027 , C12P21/04 , A61P11/00
CPC分类号： C07K16/10 , A61K48/00 , C07K14/005 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C12N2770/20022
摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
摘要翻译： 本发明涉及特异性结合人SARS-CoV S蛋白的人抗体及其抗原结合部分的抗体，其功能是中和SARS-CoV。 本发明还涉及双特异性，衍生化的单链抗体或融合蛋白部分的抗体。 本发明还涉及衍生自人抗SARS-CoV S蛋白抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗SARS-CoV S蛋白抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。
-
公开(公告)号：US08722637B2
公开(公告)日：2014-05-13
申请号：US10572582
申请日：2004-09-22
申请人： Bellur S. Prabhakar
发明人： Bellur S. Prabhakar
CPC分类号： C07K14/4703 , A61K38/1709 , C07K14/82 , C07K16/18
摘要： Methods and compositions relating to IG20 expression, splice variants of IG20, effects of endogenous DENN-SV function with respect to processes regulating cell proliferation, cell survival and cell death are disclosed.
摘要翻译： 公开了与IG20表达相关的方法和组合物，IG20的剪接变体，内源性DENN-SV功能对调节细胞增殖，细胞存活和细胞死亡的过程的影响。
-
公开(公告)号：US20130236464A1
公开(公告)日：2013-09-12
申请号：US13843123
申请日：2013-03-15
IPC分类号： C07K16/46
CPC分类号： C07K16/2818 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/28 , C07K16/2866 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/76
摘要： The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic β-cells.
-
4.发明授权Uses of bispecific antibody coated dendritic cells pulsed with antigens and GM-CSF in immune regulation 失效在抗原和GM-CSF中用双抗体包被的树突状细胞用免疫调节的用途公开(公告)号：US07527972B2
公开(公告)日：2009-05-05
申请号：US11560649
申请日：2006-11-16
CPC分类号： A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/5154 , C07K16/00 , C07K16/2818 , C07K2317/31 , C07K2317/74 , C12N5/064 , C12N2501/51
摘要： GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG.
摘要翻译： 免疫前施用的GM-CSF对重症肌无力（MG）的诱导产生持续的抑制作用。 这种抑制与降低的血清自身抗体水平，降低的AChR的T细胞增殖反应和FoxP3 +调节性T细胞群体的扩增有关。 操纵DC扩增调节性T细胞可用于控制自身免疫疾病如重症肌无力MG。
-
5.发明授权公开(公告)号：US08822649B2
公开(公告)日：2014-09-02
申请号：US13944036
申请日：2013-07-17
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2818 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/28 , C07K16/2866 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/76
摘要： The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic β-cells.
摘要翻译： 本公开涉及由在T细胞表面上表达的细胞毒性T淋巴细胞抗原4（CTLA-4）和葡萄糖转运蛋白2的第二特异性结合活性的第一多肽或多肽结构域具有第一特异性结合活性的蛋白质 （GLUT2）或其在胰腺细胞表面上表达的胞外结构域，其中第一多肽或多肽结构域与CTLA-4的结合在T细胞中诱导CTLA-4特异性激动剂反应，并且结合第二 GLUT2或其胞外域的多肽或多肽结构域不抑制GLUT2葡萄糖转运蛋白功能，其中T细胞中的所述激动剂反应诱导减少对胰腺细胞的免疫反应性的应答。
-
6.发明申请ANTI-CLTA4, ANTI-GLUT2 PROTEIN FOR THE TREATMENT OF TYPE 1 DIABETES 有权ANTI-CLTA4，用于治疗1型糖尿病的抗GLUT2蛋白公开(公告)号：US20130323250A1
公开(公告)日：2013-12-05
申请号：US13944036
申请日：2013-07-17
IPC分类号： C07K16/28
CPC分类号： C07K16/2818 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/28 , C07K16/2866 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/76
摘要： The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic β-cells.
摘要翻译： 本公开涉及由在T细胞表面上表达的细胞毒性T淋巴细胞抗原4（CTLA-4）和葡萄糖转运蛋白2的第二特异性结合活性的第一多肽或多肽结构域具有第一特异性结合活性的蛋白质 （GLUT2）或其在胰腺β细胞表面上表达的胞外结构域，其中第一多肽或多肽结构域与CTLA-4的结合在T细胞中诱导CTLA-4特异性激动剂应答，并且第二多肽 或多肽结构域至GLUT2或其胞外域不抑制GLUT2葡萄糖转运蛋白功能，其中T细胞中的所述激动剂反应诱导减少对胰腺β细胞的免疫反应性的应答。
-
7.发明授权公开(公告)号：US09221911B2
公开(公告)日：2015-12-29
申请号：US13843123
申请日：2013-03-15
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2818 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/28 , C07K16/2866 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/76
摘要： The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic β-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic β-cells.
摘要翻译： 本公开涉及由在T细胞表面上表达的细胞毒性T淋巴细胞抗原4（CTLA-4）和葡萄糖转运蛋白2的第二特异性结合活性的第一多肽或多肽结构域具有第一特异性结合活性的蛋白质 （GLUT2）或其在胰腺细胞表面上表达的胞外结构域，其中第一多肽或多肽结构域与CTLA-4的结合在T细胞中诱导CTLA-4特异性激动剂反应，并且结合第二 GLUT2或其胞外域的多肽或多肽结构域不抑制GLUT2葡萄糖转运蛋白功能，其中T细胞中的所述激动剂反应诱导减少对胰腺细胞的免疫反应性的应答。
-
公开(公告)号：US07728110B2
公开(公告)日：2010-06-01
申请号：US11805129
申请日：2007-05-21
CPC分类号： C07K16/10 , A61K48/00 , C07K14/005 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C12N2770/20022
摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
摘要翻译： 本发明涉及特异性结合人SARS-CoV S蛋白的人抗体及其抗原结合部分的抗体，其功能是中和SARS-CoV。 本发明还涉及双特异性，衍生化的单链抗体或融合蛋白部分的抗体。 本发明还涉及衍生自人抗SARS-CoV S蛋白抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗SARS-CoV S蛋白抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。
-
9.发明申请USES OF BISPECIFIC ANTIBODY COATED DENDRITIC CELLS PULSED WITH ANTIGENS AND GM-CSF IN IMMUNE REGULATION 审中-公开在免疫调节中用抗原和GM-CSF刺激的双重抗体包被的DENDRITIC细胞的使用公开(公告)号：US20090232854A1
公开(公告)日：2009-09-17
申请号：US12401089
申请日：2009-03-10
CPC分类号： A61K39/0008 , A61K2035/122 , A61K2039/505 , A61K2039/5154 , C07K16/00 , C07K16/2818 , C07K2317/31 , C07K2317/74 , C12N5/064 , C12N2501/51
摘要： GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG.
摘要翻译： 免疫前施用的GM-CSF对重症肌无力（MG）的诱导产生持续的抑制作用。 这种抑制与降低的血清自身抗体水平，降低的AChR的T细胞增殖反应和FoxP3 +调节性T细胞群体的扩增有关。 操纵DC扩增调节性T细胞可用于控制自身免疫疾病如重症肌无力MG。
-
公开(公告)号：US20090075929A1
公开(公告)日：2009-03-19
申请号：US12174296
申请日：2008-07-16
IPC分类号： A61K31/7105 , C07H21/02 , G01N33/566 , A61P31/00 , C07K14/00 , C12N5/06
CPC分类号： C12N15/1135 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2310/53
摘要： Methods and compositions inhibit the growth of cancer cells by selectively down-regulating the expression of an IG20 splice variant including MADD. Specific knock-down of MADD splice variant resulted in the apoptosis of cancer cells. Interfering RNAs including small hairpin RNAs (shRNA) to down-regulate MADD expression in vivo are disclosed. Inhibition of MADD phosphorylation by Akt results in activation of cancer cell death. Down-regulation of MADD expression results in switching to apoptotic mode due to lack of MAPK activation upon TNF-α-based induction.
摘要翻译： 方法和组合物通过选择性下调包括MADD的IG20剪接变体的表达来抑制癌细胞的生长。 MADD剪接变体的特异性敲低导致癌细胞凋亡。 公开了干扰RNA，包括小发夹RNA（shRNA）以体内MADD表达下调。 抑制Akt的MADD磷酸化导致癌细胞死亡的激活。 MADD表达的下调导致由于在基于TNF-α的诱导下缺乏MAPK激活而切换至凋亡模式。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.026 秒)